RecruitingPHASE1, PHASE2NCT07024316

A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP

Studying Congenital erythropoietic porphyria

Last synced from ClinicalTrials.gov May 8, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Atlas Molecular Pharma
Intervention: ATL-001 (Ciclopirox oral solution)(drug)
Enrollment: 6 enrolled
Eligibility: 18 years · All sexes
Timeline: 2026 – 2028

Study locations (1)

The Cleveland Clinics, Cleveland, Ohio, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07024316 on ClinicalTrials.gov

Other trials for Congenital erythropoietic porphyria

Additional recruiting or active studies for the same condition.

RECRUITINGNCT07567131
Observational Study of Adults and Adolescents With Erythropoietic Protoporphyria (EPP) and X-linked Porphyria (XLP)
Portal Therapeutics, Inc.

See all trials for Congenital erythropoietic porphyria →

← Back to all trials